We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Intrauterine Ultrasound Contrast Agent Tests Tubal Patency

By MedImaging International staff writers
Posted on 03 Mar 2021
Print article
Image: HyFoSy image of the uterus and fallopian tubes (Photo courtesy of ExEm Foam)
Image: HyFoSy image of the uterus and fallopian tubes (Photo courtesy of ExEm Foam)
A novel medical foam for ultrasound imaging helps assess blockages in the fallopian tubes in women with known or suspected infertility.

Intended for an ultrasound technique called hysterosalpingo foam sonography (HyFoSy), ExEm Foam, a product of ExEm Foam (Nashville, TN, USA), is an air polymer-type A intrauterine foam that offers a highly accurate, less invasive alternative to tubal patency assessment procedures such as laparoscopy or X-ray hysterosalpingography (HSG). The viscous foam is made by mixing the contents of the two ExEM syringes together. A catheter is then used to infuse this foam through the uterine cavity into the fallopian tubes during the HyFoSy procedure.

If the tubes are patent the foam will appear as a thin, bright white line within the fallopian tubes and spill over the ovaries and into the peritoneal cavity; if the white line does not appear, the fallopian tubes might be occluded or blocked. ExEm Foam should not be used during pregnancy, in women with known or suspected lower genital tract inflammation, infection, or vaginal bleeding, following a gynecologic procedure within the last 30 days, or in known or suspected reproductive tract neoplasia. Side effects include pelvic and abdominal pain, vasovagal reactions and associated symptoms such as nausea and faintness, and post-procedure spotting.

“With a growing demand for assisted reproductive technologies and a downward trend for using radiation in women trying to conceive, there is a huge need for a gentler and more patient-friendly tubal patency test,” said Johan Remmerswaal, President of ExEm Foam. “We are proud to be able to fulfill this need with the Foam procedure by quickly, safely and accurately assessing the patency of the fallopian tubes in the comfort of a patient's gynecologist office.”

“For couples experiencing infertility, we must evaluate a number of different aspects of the reproductive system to determine the root cause. Unfortunately, this evaluation can involve a lengthy process and several uncomfortable procedures,” said Professor Mark Hans Emanuel, MD, PhD, of University Medical Center Utrecht (The Netherlands), and co-inventor of ExEM Foam. “Cutting-edge, safe and effective diagnostic procedures, like the Foam procedure, allow us to quickly and as comfortably as possible identify fertility issues and plan the next step in a patient's fertility journey.”

Blockage of the fallopian tubes accounts for infertility in approximately 20% of couples who are having difficulty conceiving.

Related Links:
ExEm

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
PACS Workstation
CHILI Web Viewer
C-Arm with FPD
Digiscan V20 / V30
New
Brachytherapy Planning System
Oncentra Brachy

Print article
Radcal

Channels

MRI

view channel
Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)

Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients

Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read more

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.